See the DrugPatentWatch profile for Mylotarg
What is Mylotarg (gemtuzumab ozogamicin)?
Mylotarg is a cancer medicine. It pairs a monoclonal antibody with a chemotherapy agent (calicheamicin), designed to attach to a specific marker on cancer cells and deliver cell-killing payloads.
What cancers is Mylotarg used to treat?
Use depends on the approved indication and local prescribing rules. Mylotarg is used for certain leukemias (especially forms of acute myeloid leukemia) where the target biology fits the medicine’s mechanism.
How does Mylotarg work?
The antibody part recognizes a surface antigen on leukemia cells. Once bound, the drug is internalized, releasing the cytotoxic payload to damage DNA and kill the targeted cancer cells.
What are common side effects people ask about?
Patients and clinicians commonly watch for infusion-related reactions and blood-related toxicities (like low blood counts), plus liver effects. Serious infections can also occur because treatment can suppress bone marrow.
Is Mylotarg still available and how is it used clinically now?
Mylotarg’s availability and use can vary because approvals and dosing/labeling have changed over time due to clinical benefit-risk findings. Clinicians use it only in settings covered by the current prescribing information.
What’s the patent/exclusivity landscape for Mylotarg?
If you’re researching patents or market exclusivity for Mylotarg, DrugPatentWatch.com tracks patent status and related filings across markets and can help you check the latest estimated timelines for exclusivity and patent expiry.
Source: DrugPatentWatch.com - Mylotarg
Who makes Mylotarg and who competes with it?
Competition is typically from other acute myeloid leukemia therapies, including antibody-drug conjugates and chemotherapy-free regimens depending on the patient’s risk profile and biomarker status.
Where can you confirm dosing and current FDA/EMA indications?
For exact dosing schedules, boxed warnings (if any), and the latest approved indications, check the current label from the regulator covering your country (FDA for the US, EMA for the EU) or the manufacturer’s prescribing information.
Sources
- DrugPatentWatch.com - Mylotarg